ADAG

Adagene Inc. - ADR

2.05

USD

-0.07

-3.30%

Nov 10, 15:59 UTC -5

Closed

After-Market

2.04

-0.01

-0.49%

Adagene Inc. - ADR (ADAG) Earnings

ADAG Earnings Reports

Positive Surprise Ratio

ADAG beat 0 of 2 last estimates.

Next Report

Date of Next Report

Mar 30, 2027

Estimate for Q4 26 (Revenue/ EPS)

-$0.30

Implied change from Q2 26 (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

Adagene Inc. - ADR earnings per share and revenue

On Aug 10, 2026, ADAG reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -0.09 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 1.63 million, with a 0.00% difference.

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.30 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were Adagene Inc. - ADR's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Adagene Inc. - ADR reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.

How did the market react to Adagene Inc. - ADR's Q2 2026 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is Adagene Inc. - ADR expected to report next?

The next earning report is scheduled for Mar 30, 2027.

What are the forecasts for Adagene Inc. - ADR's next earnings report?

Based on -- analysts, Adagene Inc. - ADR is expected to report EPS of -$0.30 and revenue of -- for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.